Press Release October 31, 2019

Disc Medicine Launches with AbbVie License Agreement and $50 Million Series A Financing led by Novo Holdings A/S to Advance New Therapies Addressing Ineffective Red Blood Cell Production

The Life Sciences team advised Disc Medicine in its $50 million Series A financing and exclusive license agreement with AbbVie for the worldwide rights to a series of hemojuvelin antagonist monoclonal antibodies.

Disc Medicine is a hematology company applying new insights in hepcidin biology to develop therapies that restore red blood cell production in hematologic diseases. The company's novel approach focuses on targeting hepcidin, a key regulator of iron metabolism, as a treatment for inherited and acquired anemias. AbbVie is a global biopharmaceutical company.

The Series A financing was led by life sciences investor Novo Holdings A/S along with Access Biotechnology, the life sciences investing arm of Access Industries, and founding investor Atlas Venture. Atlas, a leading biotech venture capital firm, seeded the company in 2017.

The Goodwin team advising Disc Medicine on the financing was led by partner William Collins. The Goodwin team advising Disc Medicine on the license agreement was led by partner Sarah Solomon.

For more details, read the press releases on the financing and license agreement and articles in BioSpace and FierceBiotech.